Learn to Discover (L2D) is a cutting edge course, specifically targeted at bioscience and medicine professionals, equipping individuals with powerful skills in Python programming, data science, machine learning and aspects of AI, aimed at furthering your research.
Created and delivered by a team of expert research scientists, a rich curriculum of weekly lectures, live webinars, exercises and assignments is paired with one on one tutor guided support.
Cypex’s recombinant xenobiotic metabolizing enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.
Intellectual property offices worldwide are now enforcing the World Intellectual Property Organization (WIPO) Standard ST.26, which prescribes requirements for the presentation of nucleotide and amino acid sequence listings in patent applications. The new standard applies to patent applications filed on or after 1 July 2022 (the “big bang” date).
Leading global drug development consultancy Boyds has bolstered its US team with the appointment of experienced pharmaceutical product development professional Ami Patel PhD.
With more than 15 years’ experience in the pharmaceutical industry, Ami joins Boyds as Senior Director of Product Development based at the company’s Philadelphia office.
An independent study on European/UK growth stage Biotech remuneration
BioIVT, LLC (“BioIVT”), a leading global provider of biospecimens, cell and gene therapy related products, and research models and services for drug development purposes, today announced the promotion of Richard Haigh, PhD, to Chief Executive Officer (CEO) effective August 1. Dr. Haigh joined BioIVT in May 2022 as Chief Operating Officer and brings over 27 years’ experience in the life science research and diagnostics space covering products, consumables, and services, including over 15 years with Thermo Fisher Scientific/Life Technologies.
Cambridge UK: 27 July 2022
RSM UK has become the latest Partner to join forces with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of One Nucleus Members, the Partner and One Nucleus in delivering on its core remit of supporting innovation.
Laragh Jeanroy, Managing Partner RSM East Anglia and Co-Head of Life Sciences at RSM commented
Author: Helen Baxter, Vice President, North Highland
I joined fellow Life Science enthusiasts at the OnHelix conference in Cambridge at the beginning of the month to listen and learn to some of the latest thinking in Innovation in the industry. A range of experts talked about BioInnovation in the pharma and biotech industry at the latest OnHelix conference in Cambridge July 2022. Here are some of the key themes that emerged from the conference.
Cambridge, 28th July 2022: Cambridge-based property developer and investor Howard Group is pleased to announce Sian Steele as its new Board Chair.
Sian will take up the position from 1st August after serving for the past two years as a Non-Executive Director of the Group.